Reuters logo
BRIEF-AstraZeneca Naloxegol trial shows no imbalances in adverse effects
February 26, 2013 / 7:16 AM / 5 years ago

BRIEF-AstraZeneca Naloxegol trial shows no imbalances in adverse effects

LONDON, Feb 26 (Reuters) - AstraZeneca PLC : * Announces results from long-term safety trial of Naloxegol in patients with

opioid-induced constipation * The Naloxegol trial reported no imbalances in serious adverse events * Naloxegol commercialisation and launch in U.S. subject to

both FDA approval and DEA schedule determination

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below